BIBCL

Bharat Immunologicals & Biologicals financials

Market cap
₹75 Cr

Quarterly results

Q2 FY24: revenue down 100.0%, net profit down 59.7% against the same quarter last year.

₹ Cr · quarterly
Line itemQ3 FY22Q4 FY22Q1 FY23Q2 FY23Q3 FY23Q4 FY23Q1 FY24Q2 FY24
Revenue17 22 10 26 0 −100%8 −65%0 −100%0 −100%
EBITDA1 -4 -5 -2 -5 −563%-4 −10%-4 +11%-5 −87%
Net profit-0 -4 -5 -3 -5 −1318%-4 +9%-5 +8%-5 −60%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −30.4% 1Y

₹14.0₹16.0₹18.0₹20.0₹22.0Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹21.7 on 10 Sept 2025 → ₹15.11. High ₹22.18 (11 Sept 2025), low ₹14.25 (30 Mar 2026).

Financials, as filed

Revenue fell 43.1% a year over 1 year, FY22 to FY23. Operating margin narrowed to -36.0%.

Year endingFY22FY23
Revenue₹78 Cr₹45 Cr
Operating profit₹-5 Cr₹-16 Cr
Operating margin-6.5%-36.0%
Interest₹6 Cr₹7 Cr
Depreciation₹0 Cr₹0 Cr
Net profit₹-12 Cr₹-17 Cr
Net margin-15.4%-37.3%
Cash from operations₹-42 Cr₹11 Cr
Free cash flow₹-42 Cr₹11 Cr
ROCE-3.0%-9.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY18FY19FY20FY21FY22FY23
Equity capital₹43 Cr₹43 Cr₹43 Cr₹43 Cr₹43 Cr₹43 Cr
Reserves₹-6 Cr₹-12 Cr₹-23 Cr₹-9 Cr₹62 Cr₹36 Cr
Borrowings₹0 Cr₹32 Cr₹3 Cr₹27 Cr₹78 Cr₹74 Cr
Other liabilities₹16 Cr₹62 Cr₹103 Cr₹43 Cr₹29 Cr₹35 Cr
Total liabilities₹53 Cr₹125 Cr₹127 Cr₹104 Cr₹213 Cr₹188 Cr
Fixed assets₹5 Cr₹5 Cr₹4 Cr₹4 Cr₹116 Cr₹115 Cr
Capital work in progress₹0 Cr₹0 Cr₹0 Cr₹32 Cr₹0 Cr₹0 Cr
Investments₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Other assets₹48 Cr₹120 Cr₹122 Cr₹68 Cr₹97 Cr₹73 Cr
Total assets₹53 Cr₹125 Cr₹127 Cr₹104 Cr₹213 Cr₹188 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Mar 2024

The ownership split has held steady since Mar 2023.

Promoters
59.3%
Public
40.7%

Since Mar 2023

  • Promoters 0.00 pp
  • DIIs 0.00 pp
  • Public 0.00 pp

How it drifted, 12 quarters

Jun '21Sep '22Mar '24

Ownership split by quarter, oldest first. Jun '21: Promoters 59.3%, Public 40.8%.Sep '21: Promoters 59.3%, Public 40.8%.Dec '21: Promoters 59.3%, Public 40.8%.Mar '22: Promoters 59.3%, Public 40.8%.Jun '22: Promoters 59.3%, Public 40.8%.Sep '22: Promoters 59.3%, Public 40.8%.Dec '22: Promoters 59.3%, Public 40.8%.Mar '23: Promoters 59.3%, Public 40.7%.Jun '23: Promoters 59.3%, Public 40.7%.Sep '23: Promoters 59.3%, Public 40.8%.Dec '23: Promoters 59.3%, Public 40.8%.Mar '24: Promoters 59.3%, Public 40.7%.

Who was buying across the market this quarter →

Who is on the register

Named in the Mar 2024 filing

Every holder of Bharat Immunologicals & Biologicals above SEBI's 1% disclosure line, and what changed since Dec 2023.

HolderStakeChange
President Of India 59.25%unchanged
Dr Rajesh S Gokhale, Secretary Dbt 0.00%unchanged
Sh Vishwajit Sahay As&Fa, Dbt 0.00%unchanged
Dr Sanjay Mishra, Scientist H, Dbt 0.00%unchanged
Dr Alka Sharma, Scientist H, Dbt 0.00%unchanged
Dr Dhananjay Tiwary, Scientist G, Dbt 0.00%unchanged
Dr Nitin K Jain, Scientist G, Dbt 0.00%unchanged
Sh Pankaj Upadhyay, Ds, Dbt 0.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Learn to analyse Bharat Immunologicals & Biologicals

Guides on how to read this kind of business and the numbers that matter.